R/R AML & Venetoclax | Luspatercept for Erythropoiesis | How to Treat wAIHAMarch 16, 2021 | Oncology Hematology Clinical and Molecular Predictors of Response and Survival Following Venetoclax Therapy in R/R AML In this “Clinical Trials & Observations” report/visual abstract from the pages of Blood Advances (ASH), the authors focus on two key points: 1) In patients with R/R AML, venetoclax combination therapy resulted in responses in 31% of patients and a median OS of 6.1 months, and 2) NPM1 mutations predicted higher response rates; adverse cytogenetics and mutations in TP53, KRAS/NRAS, and SF3B1 predicted worse OS. Read full article Hematology Development of Luspatercept to Treat Ineffective Erythropoiesis This “Clinical Trials & Observations” report from Blood Advances (ASH) explores the implications of the recently approved anemia treatment luspatercept, which can now be prescribed in the second-line setting after erythropoiesis-stimulating agents (ESAs) have failed or for patients who are not eligible because of high serum erythropoietin (sEPO) levels. A downloadable visual abstract helps paint the picture as well. Read full article Hematology How I Treat Warm Autoimmune Hemolytic Anemia Warm autoimmune hemolytic anemia (wAIHA) is the most prevalent form of autoimmune hemolytic anemia (AIHA), accounting for 60% to 70% of all cases. In this special instructional series from Blood (ASH), five patient case studies and commentaries are examined, backed by visual illustrations and new/existing drug treatment tables for wAIHA, wAIHA secondary to CLL, and R/R wAIHA. Read full article
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS